Phaseline

Targets › ENPP1

ENPP1 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 1): drug programs, companies and trials

5 programs from 5 companies in 9 trials: 4 Phase 1, 3 Phase 2, 1 Phase 4, 1 Phase 3; Oncology, Gastroenterology, Other; next expected readout Apr 2027.

Nucleotide pyrophosphatase that generates diphosphate (PPi) and functions in bone mineralization and soft tissue calcification by regulating pyrophosphate levels (By similarity). PPi inhibits bone mineralization and soft tissue calcification by binding to nascent hydroxyapatite crystals, thereby preventing further growth of these crystals. (UniProt, P22413)

Open in Phaseline: the race on ENPP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Colgate Palmolivesodium monofluorophosphate toothpaste
Fluoride source for dental remineralization and caries prevention
ENPP1Phase 4Gingivitis–
Inozyme PharmaINZ-701
Recombinant ENPP1-Fc fusion protein
ENPP1Phase 3Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency; Gene Mutations; Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency–
RiboscienceRBS2418
Ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1) inhibitor that increases cGAMP
ENPP1Phase 2Advanced Unresectable Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Advanced CancerApr 2027
Arjun Deb, MDAD-NP1
humanized monoclonal antibody targeting the catalytic domain of human ENPP1
ENPP1Phase 1Maximum Tolerated DoseJan 2028
Stingray TherapeuticsSR-8541A
ENPP1 inhibitor
ENPP1Phase 1Advanced / Metastatic Solid Tumor–

Conditions

Advanced Unresectable Hepatocellular Carcinoma (1) Metastatic Colorectal Cancer (1) Advanced Cancer (1) Gingivitis (1) Advanced / Metastatic Solid Tumor (1) Maximum Tolerated Dose (1) Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency (1) Gene Mutations (1) Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency (1)

Modalities

small molecule (4), mixed (1)

Companies

Riboscience (1) Colgate Palmolive (1) Stingray Therapeutics (1) Arjun Deb, MD (1) Inozyme Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.